AbstractIn high-income countries the public policy consensus is that costs of delivering high-quality equitable cancer care present an increasing challenge to national budgets. In the U.S. alone it is estimated cancer care expenditures in 2020 will be 157 billion dollars. The increase is being driven by a number of factors including technological innovation, rising costs of medical and hospital care, expensive therapeutics and an increase in the proportion of individuals susceptible to malignancy as the population ages. In this article we review what factors are informing and influencing the political debate on cancer economics across Europe and North America.We have undertaken a comprehensive analysis of the literature and supplemented thi...
BACKGROUND: In 2008, 2·45 million people were diagnosed with cancer and 1·23 million died because of...
Background In 2008, 2.45 million people were diagnosed with cancer and 1.23 million died because of...
Abstract Background Health system expenditure on cancer drugs is rising rapidly in many OECD countri...
AbstractIn high-income countries the public policy consensus is that costs of delivering high-qualit...
The burden of cancer is growing, and the disease is becoming a major economic expenditure for all de...
The burden of cancer is growing, and the disease is becoming a major economic expenditure for all de...
The burden of cancer is growing, and the disease is becoming a major economic expenditure for all de...
The burden of cancer is growing, and the disease is becoming a major economic expenditure for all de...
The burden of cancer is growing, and the disease is becoming a major economic expenditure for all de...
The burden of cancer is growing, and the disease is becoming a major economic expenditure for all de...
BackgroundCancer poses a significant mortality, morbidity, economic and humanistic burden to patient...
Abstract Background Spending on cancer drugs has risen dramatically in recent years compared to othe...
Cancer is one of the leading causes of death globally and expenditure associated with cancer is quit...
Background: Spending on cancer drugs has risen dramatically in recent years compare...
Background: The rising cost of cancer drugs are a challenge for health systems, providers, and somet...
BACKGROUND: In 2008, 2·45 million people were diagnosed with cancer and 1·23 million died because of...
Background In 2008, 2.45 million people were diagnosed with cancer and 1.23 million died because of...
Abstract Background Health system expenditure on cancer drugs is rising rapidly in many OECD countri...
AbstractIn high-income countries the public policy consensus is that costs of delivering high-qualit...
The burden of cancer is growing, and the disease is becoming a major economic expenditure for all de...
The burden of cancer is growing, and the disease is becoming a major economic expenditure for all de...
The burden of cancer is growing, and the disease is becoming a major economic expenditure for all de...
The burden of cancer is growing, and the disease is becoming a major economic expenditure for all de...
The burden of cancer is growing, and the disease is becoming a major economic expenditure for all de...
The burden of cancer is growing, and the disease is becoming a major economic expenditure for all de...
BackgroundCancer poses a significant mortality, morbidity, economic and humanistic burden to patient...
Abstract Background Spending on cancer drugs has risen dramatically in recent years compared to othe...
Cancer is one of the leading causes of death globally and expenditure associated with cancer is quit...
Background: Spending on cancer drugs has risen dramatically in recent years compare...
Background: The rising cost of cancer drugs are a challenge for health systems, providers, and somet...
BACKGROUND: In 2008, 2·45 million people were diagnosed with cancer and 1·23 million died because of...
Background In 2008, 2.45 million people were diagnosed with cancer and 1.23 million died because of...
Abstract Background Health system expenditure on cancer drugs is rising rapidly in many OECD countri...